Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-08-2016 | Retinal Disorders

Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy

Authors: Hae Min Kang, Hyoung Jun Koh, Sung Chul Lee

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2016

Abstract

Purpose

To investigate the predictive factors for recurrence of polypoidal choroidal vasculopathy (PCV).

Methods

The medical records of 78 consecutive patients (78 eyes) with treatment-naïve PCV who responded to first-line treatment and completed at least a 3-year follow-up after the first remission were retrospectively analyzed. In this comparative cohort study, baseline characteristics were compared between the patients who had at least one recurrence (the recurrence group) and those without recurrence (the non-recurrence group) during at least 3-year follow-up periods. In addition, possible predictive factors for recurrence of PCV were investigated by using Cox regression analysis.

Results

Within 3 years of the first remission, 50 eyes (64 %) showed at least one recurrence (mean 1.5; 1 to ∼2 times). There were no significant differences in the baseline characteristics between the recurrence group and the non-recurrence group. However, the largest polyp diameter was significantly different: the mean largest polyp diameter (524 ± 340 μm) was significantly larger in the recurrence group compared to that of the non-recurrence group (352 ± 173 μm; P = 0.038). Cox regression analysis showed that the largest polyp diameter at baseline significantly correlated with recurrence of PCV (B = 1.470, P = 0.015).

Conclusions

The largest polyp diameter at baseline may be predictive for PCV recurrence, as it was significantly larger in patients who had at least one recurrence.

Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8CrossRefPubMed

Immamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55:501–515CrossRef

Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110CrossRefPubMed

Yannuzzi LA, Ciadella A, Spaide RF, Rabb M, Freund KB, Orlock DA (1997) The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 115:478–485CrossRefPubMed

Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, Freund KB, Slakter JS, Guyer DR, Sorenson JA, Fisher Y, Maberley D, Orlock DA (1999) Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 117:1503–1510CrossRefPubMed

Byeon SH, Lee SC, Oh HS, Kim SS, Koh HJ, Kwon OW (2008) Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol 52:57–62CrossRefPubMed

Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, Uyama M (2003) Polypoidal choroidal vasculopathy. Incidence, demographic features, and clinical characteristics. Arch Ophthalmol 121:1392–1396CrossRefPubMed

Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22CrossRefPubMed

Khan S, Engelbert M, Imamura Y, Freund KB (2012) Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings. Retina 32:1057–1068CrossRefPubMed

10.

Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R (2007) Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 27:589–584CrossRefPubMed

11.

Tsujikawa A, Sasahara M, Otani A, Gotoh N, Kameda T, Iwama D, Yodoi Y, Tamura H, Mandai M, Yoshimura N (2007) Pigment epithelial detachment in polypoidal choroidal vasculopathy. Am J Ophthalmol 141:102–111CrossRef

12.

Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, Takahashi K, Matsumura M (2002) Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 133:639–648CrossRefPubMed

13.

Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29:19–29CrossRefPubMed

14.

Kang HM, Kim YM, Koh HJ (2013) Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 115:438–447CrossRef

15.

Kang HM, Koh HJ, Lee CS, Lee SC (2014) Combined photodynamic therapy with Intravitreal Bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome. Am J Ophthalmol 157:598–606CrossRefPubMed

16.

Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 111:1576–1584CrossRefPubMed

17.

Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141–146CrossRefPubMed

18.

Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A, Nakayama Y, Yoshimura N (2012) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with Intravitreal injections of Ranibizumab. Am J Ophthalmol 153:68–80CrossRefPubMed

19.

Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A (2013) Comparison of the effect of Ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 156:644–651CrossRefPubMed

20.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H (2012) One-year results of three monthly Ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 154:117–124CrossRefPubMed

21.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Kitamei H, Shioya S (2013) Results of 2 years of treatment with as-needed Ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 97:617–621CrossRefPubMedPubMedCentral

22.

Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ (2011) One-year outcomes of Intravitreal Bevacizumab (Avastin) therapy for polypoidal choroidal vasculopathy. Retina 31:846–856CrossRefPubMed

23.

Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Long-term outcome of Intravitreal Ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye 27:1013–1020CrossRefPubMedPubMedCentral

24.

Koh AH, Expert PCV Panel, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, Kim H, Yuk Yau Lai T, Lee WK, Li X, Han Lim T, Ruamviboonsuk P, Sharma T, Tang S, Yuzawa M (2013) Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 33:686–716CrossRefPubMed

25.

Akaza E, Mori R, Yuzawa M (2008) Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 28:717–722CrossRefPubMed

26.

Akaza E, Yuzawa M, Mori R (2011) Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 55:39–44CrossRefPubMed

27.

Leal S, Silva R, Figueira J, Cachulo ML, Pires I, de Abreu JR, Cunha-Vaz JG (2010) Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up. Retina 30:1197–1205CrossRefPubMed

28.

Kang HM, Koh HJ (2013) Long-term visual outcome and prognostic factors after Intravitreal Ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 156:652–660CrossRefPubMed

29.

Cackett P, Wong D, Yeo I (2009) A classification system for polypoidal choroidal vasculopathy. Retina 29:187–191CrossRefPubMed

30.

Tsujikawa A, Ojima Y, Yamashiro K, Nakata I, Ooto S, Tamura H, Nakanishi H, Hayashi H, Otani A, Yoshimura N (2011) Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am J Ophthalmol 151:961–972CrossRefPubMed

31.

Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, Chen MS (2012) Photodynamic therapy with or without Intravitreal Bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up. Am J Ophthalmol 154:872–880CrossRefPubMed

32.

Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S (2011) Predictive factors of resolved retinal fluid after Intravitreal Ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 95:1555–1559CrossRefPubMed

33.

Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, Matsushita R, Takami K (2011) Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy. Retina 31:857–865CrossRefPubMed

34.

Saito M, Iida T, Kano M, Itagaki K (2014) Five-year results of photodynamic therapy with and without supplementary antivascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 252:227–235CrossRefPubMed

35.

Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW (2004) Photodynamic therapy with verteporfin for polypoidal vasculopathy of the macula. Ophthalmologica 218:193–201CrossRefPubMed

36.

Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG (2005) Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 243:973–979CrossRefPubMed

37.

Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R (2007) Role of photodynamic therapy in polypoidal choroidal vasculoopathy. Jpn J Ophthalmol 51:270–277CrossRefPubMed

38.

Lai TY, Lee GK, Luk FO, Lam DS (2011) Intravitreal Ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 31:1581–1588CrossRefPubMed

39.

Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with Ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94:297–301CrossRefPubMed

40.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration. Two-year results. Ophthalmology 119:1388–1398CrossRef

Title: Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy
Authors: Hae Min Kang
Hyoung Jun Koh
Sung Chul Lee
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-015-3241-6

At a glance: The STEP trials

Springer Medicine

Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2016

Modified canaloplasty with suprachoroidal drainage versus conventional canaloplasty—1-year results

Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy

Subretinal implantation of a monolayer of human embryonic stem cell-derived retinal pigment epithelium: a feasibility and safety study in Yucatán minipigs

Simvastatin use associated with low intraocular ADP levels in patients with sight-threatening diabetic retinopathy

Charles Bonnet’s syndrome: not only a condition of the elderly

Optical coherence tomography angiography in patients with polypoidal choroidal vasculopathy